Med (New York, N.Y.)Oct 30, 2026

Using Metabolic Profiles to Guide Alzheimer's and Parkinson's Disease Trials Based on Disease Mechanisms

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Nov 2, 2026

Abstract

Metabolically targeted therapies for Alzheimer's and Parkinson's disease have shown mixed results, potentially due to trial-design issues.

Three interconnected axes of metabolic dysfunction may be involved: insulin signaling, cellular energy production, and lipid-lysosomal processes.
Therapeutics have often been tested in broad populations without focusing on specific biological characteristics.
Endpoints in trials frequently do not align closely with the targeted mechanisms of treatment.
A metabolic endotype, defined as a measurable pattern of metabolic dysfunction, may exist across subsets of both diseases.
Failure to focus on this endotype in trials could weaken the detection of therapeutic effects.
A proposed four-tier framework aims to enhance the design of trials by integrating risk factors, metabolic assessments, and detailed biological profiling.

Simplified

Metabolically targeted therapies for Alzheimer's disease and Parkinson's disease have yielded mixed results despite convergent evidence implicating three interconnected axes of metabolic dysfunction: insulin signaling, cellular bioenergetics, and lipid-lysosomal biology. We argue that this pattern partly reflects a trial-design problem: therapeutics such as glucagon-like peptide 1 receptor agonists, terazosin, and stearoyl-CoA desaturase inhibitors generally have been tested in biologically unselected populations, with endpoints often distal to the targeted mechanism. We propose as a testable hypothesis that a metabolic endotype-a measurable, biomarker-supported pattern of metabolic dysfunction-spans subsets of both diseases and that failure to enrich for this endotype could dilute therapeutic signals in all-comer trials. We outline a modular four-tier framework integrating prodromal risk, metabolic vulnerability, pathway-specific confirmation, and mechanistic deep phenotyping to make Alzheimer's and Parkinson's disease trials more interpretable and therapeutically informative.

Full Text

Full text is available at the source.

View Full Text ↗

Using Metabolic Profiles to Guide Alzheimer's and Parkinson's Disease Trials Based on Disease Mechanisms

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief